Development of a Novel Peptide-Based PET Tracer [<sup>68</sup>Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma-Reference-Cited by-同舟云学术

Development of a Novel Peptide-Based PET Tracer [⁶⁸Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma

Published:2024-08-21 Issue:17 Volume:67 Page:15118-15130
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Song Lele¹,Jiang Sujun²,Yang Qi¹,Huang Wenpeng¹,Qiu Yongkang¹,Chen Zhao¹,Sun Xinyao¹,Wang Tianyao¹,Wu Sitong¹,Chen Yongshou³,Zeng Huajie²,Wang Zihua²³^ORCID,Kang Lei¹^ORCID

Affiliation:

1. Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China

2. Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350122, China

3. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China

Funder

Fujian Medical University

National Natural Science Foundation of China

National High Level Hospital Clinical Research Funding

Beijing Municipal Science and Technology Commission

Beijing Science Foundation for Distinguished Young Scholars

Joint Funds for the Innovation of Science and Technology Fujian Province

Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00759

Reference51 articles.

1. IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation

2. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7

3. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma

4. Value of susceptibility-weighted imaging in differentiating benign from malignant portal vein thrombosis

5. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy